Results 1 to 10 of about 188,535 (344)
Non-alcoholic fatty liver disease [PDF]
BMC Medicine, 2017 Non-alcoholic fatty liver disease has emerged a major challenge because of it prevalence, difficulties in diagnosis, complex pathogenesis, and lack of approved therapies. As the burden of hepatitis C abates over the next decade, non-alcoholic fatty liver disease will become the major form of chronic liver disease in adults and children and could become
L, Bukmir +4 more
core +8 more sources
Non-alcoholic fatty liver disease [PDF]
The Lancet, 2021 Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of 25% and is a leading cause of cirrhosis and hepatocellular carcinoma. NAFLD encompasses a disease continuum from steatosis with or without mild inflammation (non-alcoholic fatty liver), to non-alcoholic steatohepatitis (NASH), which is characterised by necroinflammation and faster ...
Elizabeth E, Powell +2 more
exaly +5 more sources
Non-alcoholic fatty liver disease [PDF]
Nursing Standard, 2016 Essential facts Non-alcoholic fatty liver disease (NAFLD) is an excess of fat in the liver that is not the result of excessive alcohol consumption or other secondary causes, such as hepatitis C. According to the National Institute for Health and Care Excellence, fatty liver - steatosis - affects between 20% and 30% of the population and its prevalence ...
Thomas Marjot, Jeremy Cobbold
core +8 more sources
Non alcoholic fatty liver disease
Annals of Hepatology, 2009 A 45 year old man with known hypertension, type 2 diabetes mellitus, and central obesity presents with fatigue and mild discomfort in the abdominal right upper quadrant. Repeated blood tests show a persistent alanine aminotransferase concentration of 100 IU/l (reference range 10-50) and a γ glutamyl transferase concentration of 80 IU/l (range 10-50 ...
Nahum Méndez-Sánchez
doaj +5 more sources
Statins and non‐alcoholic fatty liver disease [PDF]
Liver International, 2019 Dear Editor, In April 9 issue, van den Berg et al1 report interesting results on the indication for lipid‐lowering treatment in a large cohort with suspected non‐alcoholic fatty liver disease (NAFLD) within the population‐based Lifelines Cohort Study.
Angelico F +3 more
openaire +4 more sources
The association of vitamin D deficiency with non-alcoholic fatty liver disease [PDF]
Clinics, 2014 OBJECTIVE: Vitamin D deficiency has been related to diabetes, hypertension, hyperlipidemia and peripheral vascular disease. In this study, we aimed to investigate the role of vitamin D status in non-alcoholic fatty liver disease.
Metin Küçükazman +13 more
doaj +5 more sources
Characterization of the gut mycobiome in patients with non-alcoholic fatty liver disease and correlations with serum metabolome [PDF]
BMC MicrobiologyBackground Emerging evidence suggests that the gut microbiome plays a key role in metabolic diseases such as non-alcoholic fatty liver disease, yet the contribution of the gut mycobiome remains largely overlooked.
Ning Zheng +12 more
doaj +2 more sources
Non-Alcoholic Fatty Liver Disease [PDF]
Vnitřní lékařství, 2019 Non-alcoholic fatty liver disease (NAFLD), the hepatic manifestation of a metabolic syndrome, is a leading cause of chronic liver disease worldwide with prevalence 17-46 % in adult population. NAFLD is associated with type 2 diabetes, obesity and genetic factors and includes a spectrum of potentially progressive liver disease that comprises of simple ...
Farrell, Geoffrey +3 more
+8 more sources
Non-alcoholic fatty liver disease [PDF]
Clinical Medicine, 2018 Non-alcoholic fatty liver disease (NAFLD) has a global prevalence of about 25%. Incidence is increasing with rising levels of obesity, type 2 diabetes and the metabolic syndrome, and NAFLD is predicted to become the leading cause of cirrhosis requiring liver transplantation in the next decade.
Maurice, J, Manousou, P
+8 more sources
Frontiers in Medicine, 2022 Background:Non-alcoholic fatty liver disease (NAFLD) is a global health problem affecting more than a quarter of the entire adult population. Both monocytes and high-density lipoprotein cholesterol (HDL-C) were found to participate in the progression of ...
Liping Wang +8 more
doaj +1 more source